hemotune raises CHF 7.25 million Series B1 funding

We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally. 

Sedimentum closes its next financing round of CHF 3.3 Mio.

Only six months after closing its seed round of CHF 2.1 million, the successful healthtech start-up closes its pre-series A financing round of CHF 3.3 million. With this new capital, Sedimentum intends to conquer the Swiss B2C market with its intelligent SAFE-living solution.

Resistell AG announces completion of clinical pilot Performance Evaluation Study

We’re delighted to announce that our portfolio startup Resistell AG has completed the pilot phase of its clinical Performance Evaluation
Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.

Announcing an exciting, unique & customer-focused collaboration

We’re delighted to announce a new collaboration between HEMEX and The Bioinformatics CRO which will provide an even more complete CRO service for our start-ups! Find out how this collaboration can support you throughout your Clinical Development phase.

How can we make the Informed Consent Form process more patient-friendly?

Complicated words and sentences may be misunderstood and are very often unfamiliar to the patients. This led us to discuss how we could find the optimal solution for all parties involved in a clinical study: the patient, physician, and sponsor/CRO.